| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHPSYC.1989.01810010025004 |
| P698 | PubMed publication ID | 2910220 |
| P2093 | author name string | Hill JL | |
| Insel TR | |||
| Murphy DL | |||
| Benkelfat C | |||
| Zohar J | |||
| Grover G | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clomipramine | Q58713 |
| obsessive-compulsive disorder | Q178190 | ||
| P304 | page(s) | 23-28 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action | |
| P478 | volume | 46 |
| Q36636744 | 5-HT1A partial agonists. What is their future? |
| Q58451556 | 5HT2C CYS23/SER23 polymorphism is not associated with obsessive–compulsive disorder |
| Q28277447 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results |
| Q44552628 | Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial |
| Q44341181 | Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine |
| Q36916929 | Brain regional α-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder |
| Q55163173 | Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline. |
| Q48568541 | Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial |
| Q35326801 | Comparative efficacy of antidepressants |
| Q45075879 | Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder |
| Q33921668 | Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities |
| Q41696830 | Effective use of anxiolytics in older adults. |
| Q37111879 | Escitalopram in the treatment of obsessive-compulsive disorder |
| Q42441390 | In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex |
| Q78440673 | Influence of the serotonin antagonist, metergoline, on the anxiogenic effects of carbon dioxide, and on heart rate and neuroendocrine measures, in healthy volunteers |
| Q51095369 | Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. |
| Q30498546 | Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD |
| Q37754215 | Kleptomania: clinical characteristics and associated psychopathology. |
| Q48192113 | Mapping of SPECT regional cerebral perfusion abnormalities in obsessive-compulsive disorder |
| Q45193306 | Metergoline abolishes the prolactin response to buspirone |
| Q36200991 | Minority participation in randomized controlled trials for obsessive-compulsive disorder |
| Q33708222 | Neurobiology of childhood obsessive-compulsive disorder. |
| Q37535918 | Neurobiology of obsessive compulsive disorder--a serotonergic basis of Freudian repression |
| Q89989620 | New drugs are not enough‑drug repositioning in oncology: An update |
| Q35904680 | Obsessive compulsive disorder: a clinical update |
| Q36771320 | Obsessive-compulsive disorder. Characteristic features, pharmacologic management |
| Q24240552 | Pharmacotherapy for trichotillomania |
| Q33708237 | Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. |
| Q33546754 | Possible role of neuropeptides in obsessive compulsive disorder |
| Q48385357 | Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses |
| Q30359998 | Psychedelics |
| Q30470922 | Psychiatric symptom-provoking studies: an ethical appraisal |
| Q32144286 | Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. |
| Q41971125 | Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. |
| Q38964747 | Schizo-obsessive spectrum disorders: an update |
| Q51095171 | Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. |
| Q38004480 | Serotonin in obsessions, compulsions, and the control of aggressive impulses |
| Q52913804 | Serotonin involvement in the spontaneous alternation ability: a behavioral study in tryptophan-restricted rats |
| Q48346525 | Sleep in obsessive compulsive disorder: polysomnographic studies under baseline conditions and after experimentally induced serotonin deficiency |
| Q43977400 | Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists |
| Q33708209 | The inheritance of obsessive-compulsive disorder. |
| Q41140715 | The organization of serotonergic projections to cerebral cortex in primates: Retrograde transport studies |
| Q48389932 | The tricyclic antidepressant clomipramine dose-dependently reduces regional cerebral metabolic rates for glucose in awake rats |
| Q36703810 | Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder |
Search more.